- Home
- IOVA vs SVRA Comparison
IOVA vs SVRA Comparison
Compare IOVA & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- SVRA
- Stock Information
- Founded
- IOVA 2007
- SVRA 2007
- Country
- IOVA United States
- SVRA United States
- Employees
- IOVA N/A
- SVRA N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- IOVA Health Care
- SVRA Health Care
- Exchange
- IOVA Nasdaq
- SVRA Nasdaq
- Market Cap
- IOVA 597.7M
- SVRA 528.3M
- IPO Year
- IOVA N/A
- SVRA N/A
- Fundamental
- Price
- IOVA $1.75
- SVRA $2.28
- Analyst Decision
- IOVA Buy
- SVRA Buy
- Analyst Count
- IOVA 10
- SVRA 7
- Target Price
- IOVA $12.22
- SVRA $7.57
- AVG Volume (30 Days)
- IOVA 19.4M
- SVRA 2.4M
- Earning Date
- IOVA 05-08-2025
- SVRA 05-13-2025
- Dividend Yield
- IOVA N/A
- SVRA N/A
- EPS Growth
- IOVA N/A
- SVRA N/A
- EPS
- IOVA N/A
- SVRA N/A
- Revenue
- IOVA $212,679,000.00
- SVRA N/A
- Revenue This Year
- IOVA $83.64
- SVRA N/A
- Revenue Next Year
- IOVA $70.34
- SVRA N/A
- P/E Ratio
- IOVA N/A
- SVRA N/A
- Revenue Growth
- IOVA 11070.12
- SVRA N/A
- 52 Week Low
- IOVA $1.64
- SVRA $1.89
- 52 Week High
- IOVA $12.51
- SVRA $5.11
- Technical
- Relative Strength Index (RSI)
- IOVA 33.50
- SVRA 36.20
- Support Level
- IOVA $1.70
- SVRA $1.89
- Resistance Level
- IOVA $1.87
- SVRA $3.18
- Average True Range (ATR)
- IOVA 0.15
- SVRA 0.21
- MACD
- IOVA 0.02
- SVRA -0.11
- Stochastic Oscillator
- IOVA 27.50
- SVRA 29.77
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.